Platelet activation in patients with congestive heart failure: Do we have enough evidence to consider clopidogrel?

American Heart Journal

Volumn 145, Issue 3, 2003, Pages 397-403

  Malinin, Alex I ^a   O'Connor, Christopher M ^b   Dzhanashvili, Alec I ^a   Sane, David C ^c   Serebruany, Victor L ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENYLATE CYCLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; BRADYKININ; CD31 ANTIGEN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FIBRINOPEPTIDE A; OSTEONECTIN; PADGEM PROTEIN; PURINE P2Y RECEPTOR; STREPTOKINASE; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; VALSARTAN; VON WILLEBRAND FACTOR; WARFARIN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY STENT; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

EID: 0346665577     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.163     Document Type: Review

References (85)

1. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease: the Framingham Heart Study. N Engl J Med 1990;322:1635-41.
2. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73.
3. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998;97:282-9.
4. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
5. Williams JF Jr, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-98.
6. Levit KR, Lazenby HC, Cown CA. National health expenditures, 1990. Health Care Fin Rev 1991;13:29-54.
7. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993;126:1042-7.
8. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45:968-74.
9. Nixon JV. Left ventricular mural thrombus. Arch Intern Med 1983;143;1567-71.
10. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-31.
11. Brown A, Cleland JGF. Influence of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1998;19:1063-9.
12. Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-12.
13. Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-12.
14. Jafri SM, Riddle JM, Raman SB, et al. Altered platelet function in patients with severe congestive heart failure. Henry Ford Hosp Med J 1986;34:156-9.
15. Mehta J, Mehta P. Platelet function studies in heart disease, VI: enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation 1979;60:497-503.
16. Andreassen AK, Nordoy I, Simonsen S, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998;81:604-8.
17. Devaux B, Scholz D, Hirche A, et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-9.
18. Negrescu EV, Sazonova LN, Baldenkov GN, et al. Relationship between the inhibition of receptor-induced increase in cytosolic free calcium concentration and the vasodilator effects of nitrates in patients with congestive heart failure. Int J Cardiol 1990;26:175-84.
19. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996;26:353-70.
20. Weidinger F, Glogar D, Sochor H, et al. Platelet survival in patients with dilated cardiomyopathy. Thromb Haemost 1991;66:400-5.
21. Hsu-Lin SC, Berman CL, Furie BC, et al. A platelet membrane protein expressed during platelet activation. J Biol Chem 1984;259:9121-6.
22. Kuijper PHM, Torres HIG, Vanderlinden JAM, et al. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood 1996;87:3271-81.
23. O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-9.
24. Mehta J, Mehta P. Platelet function studies in heart disease: enhanced platelet aggregate formation in congestive heart failure. Circulation 1979;60:497-503.
25. Gibbs CR, Blann AD, Watson RD, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001;103:1746-51.
26. Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22(A Suppl):14-9A.
27. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilatation is attenuated in patients with heart failure. Circulation 1991;84:1589-96.
28. Lip GYH, Blann AD. von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995;74:580-3.
29. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
30. Lip GYH, Lowe GDO, Metcalfe MJ, et al. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995;76:453-8.
31. Newman PJ, Berndt MC, Gorsky J, et al. PECAM-1 (CD 31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990;247:1219-23.
32. Muller WA, Berman ME, Newman PJ, et al. A heterophylic adhesion mechanisms for platelet/endothellal adhesion molecule 1 (CD 31). J Exp Med 1992;175:1401-4.
33. Serebruany VL, Murugesan SR, Pothula A, et al. Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure: independence of disease etiology, and antecedent aspirin therapy. Eur J Heart Fail 1999;1:243-9.
34. Breton-Gorius J, Clezardin P, Guichard J, et al. Localization of platelet osteonectin at the internal face of the alpha-granule membranes in platelets and megakaryocytes. Blood 1992;79:936-41.
35. Garg RK, Gheorghiade M, Jafri SM. Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure. Prog Cardiovasc Dis 1998;41:225-36.
36. Anderson GM, Hull E. The use of dicumarol as an adjunct to the treatment of congestive heart failure. South Med J 1988;41:365-71.
37. Le Quan-Sang KH, David-Dufilho M, Kerth P, et al. Changes in platelet free Ca2+ concentration after chronic digoxin treatment. Fundam Clin Pharmacol 1987;1:125-34.
38. Andersson TL, Zygmunt P, Vinge E. Some substances with proposed digitalis-like effects evaluated on platelet functions sensitive for cardiac glycosides. Gen Pharmacol 1991;22:749-53.
39. Grose JH, Gbeassor FM, Lebel M. Differential effects of diuretics on eicosanoid biosynthesis. Prostaglandins Leukot Med 1986;24:103-9.
40. Rendu F, Bachelot C, Molle D, et al. Indapamide inhibits human platelet aggregation in vitro: comparison with hydrochlorothiazide. J Cardiovasc Pharmacol 1993;22(6 Suppl):S57-63.
41. Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. J Cardiovasc Pharmacol 1991;18(4 Suppl):S29-34.
42. Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ Res 1982;51:314-20.
43. de Leeuw PW, de Bos R, van Es PN, et al. Blood platelets and angiotensin II. J Hypertens 1984;2(3 Suppl):S225-6.
44. Haller H, Lüdersdorf M, Lenz T, et al. Changes in sensitivity to angiotensin II in platelets. J Cardiovasc Pharmacol 1987;10(10 Suppl):S44-7.
45. Ding YA, MacIntyre DE, Kenyon CJ, et al. Angiotensin II effects on platelet function. J Hypertens 1985;(33 Suppl):S251-3.
46. Larsson PT, Schwieler JH, Wallén NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000;1:61-9.
47. Ferri C, De Angelis C, Del Porto MA, et al. Blood platelets and angiotensin II: angiotensin II release after platelet aggregation. J Hypertens 1988;6(1 Suppl):S69-71.
48. Santucci A, Ferri C, Leonetti Luparini R, et al. Effect of angiotensin converting enzyme inhibition on platelet angiotensin II content. Am J Med 1988;84:119-21.
49. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000;45:419-29.
50. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
51. Gomi T, Ikeda T, Shibuya Y, et al. Effects of antihypertensive treatment on platelet function in essential hypertension. Hypertens Res 2000;23:567-72.
52. Moser L, Callahan KS, Cheung AK, et al. ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol 1997;30:461-7.
53. Persson K, Whiss PA, Nyhlen K, et al. Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro. Eur J Pharmacol 2000;406:15-9.
54. Hale LP, Craver KT, Berrier AM, et al. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler Thromb Vasc Biol 1998;18:1643-6.
55. Keidar S, Oiknine J, Leiba A, et al. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol 1996;27:183-6.
56. Zurbano MJ, Anguera I, Heras M, et al. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol 1999;19:1791-5.
57. Moskowitz R. The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure: fear or reality? Curr Cardiol Rep 2001;3:247-53.
58. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-9.
59. Peterson JG, Topol EJ, Sapp SK, et al. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000;109:371-7.
60. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999;33:1920-5.
61. Cohn JN, Tognoni G, Glazer RD, et al. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-60.
62. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.
63. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998;32:198-205.
64. Levy PJ, Yunis C, Owen J, et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188-92.
65. Li P, Fukuhara M, Diz DI, et al. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000;292:238-46.
66. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86:222-32.
67. Sun B, Li J, Okahara K, et al. P2X1 purinoceptor in human platelets: molecular cloning and functional characterization after heterologous expression. J Biol Chem 1998;273:11544-7.
68. Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation. J Biol Chem 1998;273:2024-9.
69. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998;273:2030-4.
70. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591-8.
71. Gachet C, Hechler B, Leon C, et al. Activation of ADP receptors and platelet function. Thromb Haemost 1997;78:271-5.
72. Cattaneo M, Canciani MT, Lecchi A, et al. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990;75:1081-6.
73. Moritz MW, Reimers RC, Baker RK, et al. Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. J Lab Clin Med 1983;101:537-44.
74. Coukell AJ, Markham A. Clopidogrel (review). Drugs 1997;54:745-50.
75. Savi P, Labouret C, Delesque N, et al. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-83.
76. Moshfegh K, Redando M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000;36:699-705.
77. Roald HE, Barstad RM, Kierulf P, et al. Clopidogrel: a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently on the blood flow conditions. Thromb Haemost 1994;71:655-62.
78. Herbert JM, Bernat A, Maffrand JP. Aprotinin reduces clopidogrel-induced prolongation of bleeding time in the rat. Thromb Res 1993;71:433-41.
79. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939-43.
80. Hechler B, Leon C, Vial C, et al. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998;92:152-9.
81. Herbert JM, Tissinier A, Defreyn G, et al. Inhibitory effects of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993;13:1171-9.
82. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992;80:2281-6.
83. Yao SK, Ober JC, Fergusson JJ, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994;267:488-93.
84. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
85. Mitka M. Results of CURE trial for acute coronary syndrome. JAMA 2001;11;285:1828-9.